PCN103 Variation in Health-Related Quality of Life by Age Among Patients With Chronic Lymphocytic Leukemia von Pashos, C.L, Flowers, C.R, Weiss, M, Lamanna, N, Farber, C, Kipps, T.J, Lerner, S, Kay, N, Sharman, J, Grinblatt, D.L, Flinn, I.W, Kozloff, M.F, Swern, A.S, Khan, Z, Street, T.K, Sullivan, K.A, Harding, G, Keating, M.J

Volltext

5003 Phase II study of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: activity and safety results von Blay, J.Y, Lluch, A, Gutierrez, M, Martin, M, Kozloff, M.F, Prady, C, Tassell, V, Kern, K, Huang, X, Verma, S

Volltext

1231 A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with so... von Kozloff, M.F, Martin, L.P, Krzakowski, M, Samuel, T.A, Tarazi, J, Rosbrook, B, Tortorici, M, Olszanski, A.J, Cohen, R.B

Volltext

141O Efficacy outcomes by age from 5 observational or phase-4 studies of bevacizumab (Bev) in metastatic colorectal cancer (mCRC) von Hubbard, J., Grothey, A., Van Cutsem, E., Hurwitz, H., Kozloff, M.F., Bekaii-Saab, T., Bennouna, J., Zafar, Y., Revil, C., Sommer, N., Srock, S., Arnold, D.

Volltext

First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the... von Miles, D.W., Kim, S.-B., Velu, T., García-Saenz, J.A., Tan-Chiu, E., Sohn, J.H., Dirix, L., Vanˇásek, J., Borms, M.V., De Mingorance, J. Ilgado, Liu, M.-C., Moezi, M.M., Kozloff, M.F., Sparano, J.A., Xu, N., Yan, Y., Wongchenko, M.J., Simmons, B., McNally, V., Brufsky, A.

Volltext

4025 POSTER A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC) von Zurita, A, Shore, N.D, Kozloff, M.F, Ryan, C.W, Beer, T.M, Chow Maneval, E, Chen, I, Logothetis, C.J

Volltext

Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: A feasible and active approach von Vokes, E. E., Haraf, D. J., McEvilly, J. M., Mick, R., Kozloff, M. F., Goldman, M. D., Moran, W. J., Clendeninn, N. J., Collier, M. A., selbaum, R. R. Weich, Panje, W. R.

Volltext

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer von Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Oettle, Helmut, Kozloff, Mark, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Gueorguieva, Ivelina, Lahn, Michael M. F., Blunt, Al, Benhadji, Karim A., Tabernero, Josep

Volltext

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer von Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Kozloff, Mark, Simionato, Francesca, Cleverly, Ann, Smith, Claire, Wang, Shuaicheng, Man, Michael, Driscoll, Kyla E., Estrem, Shawn T., Lahn, Michael M. F., Benhadji, Karim A., Tabernero, Josep

Volltext